Gastroschisis, a congenital abdominal wall defect, has transformed from a uniformly fatal condition to one with a 95% survival rate through surgical advancements over the past six decades.
FDA is poised to pull Ocaliva as adcomm documents question post-approval study results
The FDA appeared ready to pull its accelerated approval of Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva, bluntly laying out its rationale in
September 12, 2024